In vitro metabolism of MK-0767 [(±)-5-[(2,4-dioxothiazolidin-5-yl) methyl]-2-methoxy-N-[[(4-trifluoromethyl)-phenyl] methyl]benzamide], a peroxisome proliferator-activated receptor α/γ agonist. II. Identification of metabolites by liquid chromatography-tandem mass spectrometry

Drug Metabolism and Disposition

Volumn 32, Issue 9, 2004, Pages 1023-1031

  Liu, David Q ^a   Karanam, Bindhu V ^a   Doss, George A ^a   Sidler, Rick R ^a   Vincent, Stella H ^a   Hop, Cornelis E C A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; CYTOCHROME P450 3A4; DRUG METABOLITE; GLUCURONIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOG; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; MONKEY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RADIOMETRY; RAT; RING OPENING; TANDEM MASS SPECTROMETRY;

ANIMALS; CARBON RADIOISOTOPES; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; GLUCURONIDES; HAPLORHINI; HEPATOCYTES; HUMANS; MASS SPECTROMETRY; MICROSOMES, LIVER; NADP; PPAR ALPHA; PPAR GAMMA; RATS; S-ADENOSYLMETHIONINE; SULFHYDRYL COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES;

ANIMALIA; CANIS FAMILIARIS;

EID: 4143061793     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.000059     Document Type: Article

References (16)

1. Baldwin SJ, Clarke SE, and Chenery RJ (1999) Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48:424-432.
2. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, and Cowley H (2000) Absorption, distribution and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 28:772-780.
3. Fouda HG, Lukaszewicz J, Clark DA, and Hulin B (1991) Metabolism of a new thiazolidinedione hypoglycemic agent CP-68,722 in rats: metabolite identification by gas chromatography mass spectrometry. Xenobiotica 21:925-934.
4. Hackett AG, Kotyk JJ, Fujiwara H, and Logusch EW (1993) Metabolism of triallate in Sprague-Dawley rats. 3. In vitro metabolic pathways. J Agric Food Chem 41:141-147.
5. Karanam BV, Hop CECA, Liu DQ, Wallace M, Dean D, Satoh H, Komuro M, Awano K, and Vincent S (2004) In vitro metabolism of MK-0767 (5-[2,4- dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl)-phenyl] methyl]benzamide), a peroxisome proliferator-activated receptor PPAR dual agonist. I. Role of cytochrome P450, methyltransferases, flavin monooxygenases, and esterases. Drug Metab Dispos 32:1015-1022.
6. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, and Baillie TA (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 14:62-72.
7. Kersten S, Desvergne B, and Wahli W (2000) Roles of PPARs in health and disease. Nature (Lond) 405:421-424.
8. Kiyota Y, Kondo T, Maeshiba Y, Hashimoto A, Yamashita K, Yoshimura Y, Motohashi M, and Tanayama S (1997) Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs. Arzneim-Forsch/Drag Res 47:22-28.
9. Krieter PA, Colletti AE, Doss GA, and Miller RR (1994) Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metab Dispos 22:625-630.
10. Mudaliar S and Henry RR (2001) New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52:239-257.
11. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, and Kadowaki T (1998) A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ. Diabetes 47:1841-1847.
12. Nadeau RG, Chott RC, Fujiwara H, Shieh HS, and Logusch EW (1993) Metabolism of triallate in Sprague-Dawley rats. 2. Identification and quantitation of excreted metabolites. J Agric Food Chem 41:132-140.
13. Nomura M, Kinoshita S, Satoh H, Maeda T, Murakami K, Tsunoda M, Miyachi H, and Awano K (1999) 3-Substituted (benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Bioorg Med Chem Lett 9:533-538.
14. Rushmore TH, Reider PJ, Slaughter D, Assang C, and Shou M (2000) Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab Eng 2:115-125.
15. Shen Z, Reed JR, Creighton M, Liu DQ, Tang YS, Hora DF, Feeney W, Bakhtiar R, Franklin RB, and Vincent SH (2003) Identification of novel metabolites of pioglitazone in rats and dogs. Xenobiotica 33:499-509.
16. Vanden Heuvel JP (1999) Peroxisome proliferator-activated receptors (PPARs) and carcinogenesis. Toxicol Sci 47:1-8.